Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 13/20 | 0.48 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.48 |
| ▸ | ADORA3 | P0DMS8 | 6/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 6/20 | 0.43 |
| ▸ | NT5E | P21589 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.40 |
| ▸ | THPO | P40225 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10210012 | 0.82 | ADORA2A (0.51) | ADORA2AADORA1 | |
| SCHEMBL10210014 | 0.81 | ADORA2A (0.48) | ADORA2AADORA3ADORA1 | |
| SCHEMBL12964306 | 0.81 | ADORA1 (0.47) | ADORA2AADORA1 | |
| SCHEMBL12964099 | 0.81 | ADORA2A (0.43) | ADORA2AADORA3ADORA1 | |
| SCHEMBL12964305 | 0.80 | ADORA2A (0.41) | ADORA2AADORA1 | |
| SCHEMBL22826756 | 0.78 | ADORA2A (0.59) | ADORA2AADORA2BADORA3ADORA1CYP1A2 | |
| SCHEMBL280091 | 0.78 | ADORA2A (0.41) | ADORA2AADORA1 | |
| SCHEMBL12964118 | 0.78 | ADORA2A (0.64) | ADORA2AADORA2BADORA3ADORA1NT5E | |
| SCHEMBL12964098 | 0.76 | ADORA2A (0.43) | ADORA2AADORA1 | |
| SCHEMBL20615144 | 0.73 | ADORA2A (0.53) | ADORA2AADORA2BADORA3ADORA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8133880-B2 | Purine derivatives and methods of use thereof | INOTEK PHARMACEUTICALS CORPORATION (US) | 2012-03-13 | — | — | US | disclosed |
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | INOTEK PHARMACEUTICALS CORPORATION (US) | 2011-03-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110059915-A1 | PURINE DERIVATIVES AND METHODS OF USE THEREOF | PNP, NUDT1, HPRT1 | ADORA2A 4/4885ADORA2B 33/4885ADORA3 26/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.